Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has entered into a definitive agreement to acquire Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing ...

Gilead Sciences Inc. GILD shares are down on Tuesday as the company announced a $3.15 billion acquisition of Tubulis GmbH.

Gilead said on Tuesday it would acquire private Germany-based Tubulis GmbH for up to $5 billion, as the U.S. drugmaker looks to boost its pipeline with a lucrative class of ...

Foster City, California-based Gilead Sciences, Inc. (GILD) discovers, develops, and commercializes medicines in the areas of ...

Acquisition Adds Clinical Stage Bispecific BCMAxCD3 T Cell Engager with Potential for Durable Immune Reset to Gilead’s ...

Galapagos (GLPG, GLPG.AS) has entered into a binding agreement with Gilead Sciences (GILD) in connection with Gilead's agreement to acquire all of the outstanding equity ...

Foster City pharmaceuticals giant Gilead Sciences has agreed to pay a $202 million settlement over allegations in a lawsuit by state and federal authorities that it paid doctors kickbacks, sent them ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Gilead Sciences Inc. is planning to expand its campus in ...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 ...